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Granulocyte-colony stimulating factor (G-CSF) and bone marrow derived mononuclear cells
(BM-MNCs) have both been shown to improve functional outcome following experimental
stroke. These effects are associated with increased angiogenesis and neurogenesis. In
the present study, we aimed to determine synergistic effects of G-CSF and BM-NMC
treatment on long-term structural and functional recovery after photothrombotic stroke. To
model the etiology of stroke more closely, we used spontaneously hypertensive (SH) rats
in our experiment. Bone marrow derived mononuclear cells transplantation was initiated
1 h after the onset of photothrombotic stroke. Repeated G-CSF treatment commenced
immediately after BM-MNC treatment followed by daily injections for five consecutive
days. The primary endpoint was functional outcome after ischemia. Secondary endpoints
included analysis of neurogenesis and angiogenesis as well as determination of infarct
size. Granulocyte-colony stimulating factor treated rats, either in combination with BM-
MNC or alone showed improved somatosensory but not gross motor function following
ischemia. No beneficial effect of BM-MNC monotherapy was found. Infarct volumes were
comparable in all groups. In contrast to previous studies, which used healthy animals,
post-stroke neurogenesis and angiogenesis were not enhanced by G-CSF. In conclusion,
the combination of G-CSF and BM-MNC was not more effective than G-CSF alone. The
reduced efficacy of G-CSF treatment and the absence of any beneficial effect of BM-MNC
transplantation might be attributed to hypertension-related morbidity.
Keywords: stroke, spontaneously hypertensive rat (SHR), bone marrow cells, G-CSF, neuroregeneration, neuroge-
nesis, angiogenesis, functional recovery
INTRODUCTION
Stroke is a lethal disease, yet it disables more than it kills. Bet-
ter controls of risk factors in preventing stroke and improved
treatment options for those who have had a stroke are essen-
tial for diminishing its devastating consequences. There are
substantial research efforts being made to develop treatments
that improve the outcome following stroke. Both, the stimu-
lation of endogenous bone marrow cells by the granulocyte
colony-stimulating growth factor (G-CSF) and the transplan-
tation of bone marrow mononuclear cells (BM-MNCs) were
shown to enhance regeneration in a large number of animal
stroke studies (Schneider et al., 2005; Giraldi-Guimarães et al.,
2009; Diederich et al., 2012b). Mechanisms underlying G-CSF
and BM-MNC induced functional recovery after stroke include
the potentiation of endogenous neurogenesis and angiogenesis
as well as an increased dendritic plasticity (Lee et al., 2005;
Schneider et al., 2005). Granulocyte-colony stimulating factor
mediates its actions on these mechanisms by the mobilization
of bone marrow cells and by direct neuronal effects (Schnei-
der et al., 2005). The BM-MNC mode of action is assumed
to be based on their production and secretion of cytokines,
which in turn modulate endogenous repair mechanisms. We
hypothesized that the combination of G-CSF and BM-MNCs is
more effective than either treatment alone because transplanta-
tion of exogenous BM-MNCs can bridge the gap until G-CSF
mobilizes endogenous BM-MNCs into the blood. In addition,
according to its genuine function, G-CSF might increase the
survival of transplanted BM-MNCs and thereby improve their
efficacy.
Besides its pro-regenerative effects G-CSF also exerts neu-
roprotective actions in animal stroke models (Minnerup et al.,
2008; England et al., 2009; Sevimli et al., 2009; Strecker et al.,
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2010). These neuroprotective modes of action, however, could
not be confirmed in a recent clinical trial (Ringelstein et al.,
2013). In our study we focused on G-CSFs´ effects on regen-
eration rather than on neuroprotective actions. We used the
photothrombotic stroke model, which is characterized by small
and highly reproducible infarct sizes and the reliable evocation
of neuroregenerative events like neurogenesis, angiogenesis and
dendritogenesis (Carmichael, 2005). We chose spontaneously
hypertensive (SH) rats for our experiments for two reasons: first,
the use of healthy animals without comorbidities was demon-
strated to overstate the efficacy of candidate stroke treatments
and second, SH rats are syngeneic, thus transplantation of BM-
MNCs from one SH rat to another simulates autologous trans-
plantation, which might be more practical from a translational
perspective.
EXPERIMENTAL PROCEDURES
ANIMALS
All animal procedures were approved by the responsible ethics
committee of the University of Münster and the appropriate
authorities of the Federal State of North Rhine-Westphalia. The
investigations were carried out in accordance with national and
international animal welfare regulations and are reported in
accordance with the Animal Research: Reporting In Vivo Exper-
iments (ARRIVE) guidelines (Kilkenny et al., 2011). Surgery and
evaluation of all read-outs were performed blinded to experimen-
tal groups. Experiments were performed on adult (12–13 weeks
old) male SH rats weighing 260–290 g. Spontaneously hyper-
tensive rats were shown to have an increased blood pressure
starting from 5 to 6 weeks of age (Dickhout and Lee, 1998).
All animals were randomly assigned to one of the following
treatment groups: (1) placebo (n = 13); (2) G-CSF 50 µg/kg/day
(n = 14); (3) 5 million BM-MNCs/rat (n = 14); or (4) 5 mil-
lion BM-MNCs/rat and G-CSF 50 µg/kg/day (n = 14). One
animal of the placebo group died during surgery. BM-MNC
transplantation was initiated 1 h after the onset of the pho-
tothrombosis. Repeated G-CSF treatment started immediately
after BM-MNC treatment followed by daily injections for five
consecutive days.
The cell numbers used in our experiments were based on pre-
vious studies that investigated different intravenous cell therapies
in animal stroke models (Iihoshi et al., 2004; Giraldi-Guimarães
et al., 2009; Minnerup et al., 2014). The condition of animals
was monitored at least every 8 h. Pre-defined termination criteria
were: (1) a severe immobility; and (2) a persisting abnormal body
position. The implementation of these criteria was required by the
local ethics committee.
BONE MARROWMONONUCLEAR CELL PREPARATION
Bone marrow derived mononuclear cells were prepared as pre-
viously described (Minnerup et al., 2014). Briefly, syngeneic
rat bone marrow was obtained from male SH rats at the age
of 12 weeks. Femurs and tibias were aseptically opened and
repeatedly flushed with phosphate buffered saline (PBS). After
erythrocyte lysis by ammonium chloride-based buffer (0.155 M
NH4Cl, 10 mM KHCO3 and 0.01 mM Na2EDTA) cells were
filtered by a 100 µm cell strainer, counted and prepared for
immunomagnetic depletion of granulocytes: bone marrow cells
were incubated with 10 ng/ml Phycoerythrin-conjugated anti-
rat granulocyte antibody (clone RP1; BD Pharmingen, Heidel-
berg, Germany) for 15 min at 4◦C. Subsequently, cells were
washed with cold PBS plus 0.5% fetal calf serum (FCS) and
incubated with 200 µl anti-Phycoerythrin MicroBeads (Mil-
tenyi Biotech, Bergisch Gladbach, Germany) in 800 µl PBS plus
5% FCS for 15 min at 4◦C. After incubation, non-adsorbed
MicroBeads were removed by a further washing step. The cell
suspension was then resuspended in 500 µl PBS plus 0.5% FCS
and magnetically separated by a LD-column according to the
manufacturer’s instructions (Miltenyi). This procedure results in
higher BM-MNC purity compared to standard density gradi-
ent centrifugation (Pösel et al., 2012). The obtained mononu-
clear cell fraction was collected, counted, cryopreserved in liquid
nitrogen (25 million mononuclear cells in 1 ml FCS plus 8%
DMSO) and stored at −80◦C until further use. Vital cell num-
bers were determined by the trypan blue exclusion method
using a hemocytometer (Pösel et al., 2012). Cellular composition
of cell grafts was characterized by flow cytometry for B cells
(CD45R+), T cells (CD3+) and myeloid cells (CD11b+ and
RP1-).
STROKE MODEL AND THERAPY
The photothrombotic stroke model was utilized in this study
and was executed as previously described (Schmidt et al.,
2012). In brief, animals were anesthetized with an intraperi-
toneal injection of ketamine hydrochloride (100 mg/kg body
weight; Ketanest) and xylazine hydrochloride (8 mg/kg body
weight). The left femoral vein was cannulated with a PE-50
tube for Bengal Rose infusion. The rectal temperature was main-
tained at 37◦C by a thermostat-controlled heating pad (Föhr
Medical Instruments). Photothrombotic ischemia was induced
in the right frontal cortex. For illumination, a laser spot of
8 mm in diameter (G Laser Technologies) was placed stereo-
taxically onto the skull 0.5 mm anterior to the bregma and
3.5 mm lateral from the midline. The skull was illuminated
for 20 min. During the first 2 min of illumination, the dye
Bengal Rose (0.133 mL/kg body weight, 10 mg/mL saline) was
injected intravenously. One hour after onset of the photothrom-
bosis animals received BM-MNCs or vehicle intravenously. Ani-
mals of the respective treatment groups received treatment
with G-CSF or saline daily for five consecutive days starting
immediately after BM-NMC-treatment. To label dividing cells,
each animal received a daily bromodeoxyuridine (BrdU) injec-
tion (50 mg/kg per day intraperitoneally) throughout the 5-
day treatment period, 1 h before the respective G-CSF or saline
injection.
FUNCTIONAL TESTING
Behavioral testing was conducted as previously described
(Diederich et al., 2012a). In all animals, behavioral tests were
performed before ischemia (baseline) as well as on days 1, 7,
14, 21, and 28 after ischemia by an investigator blinded to the
experimental groups.
Motor deficits were examined by means of the cylinder test.
For this purpose, the rats were placed into a transparent cylinder
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and videotaped from below for 3 min. Spontaneous wall and
ground touches of the forepaws were counted. An asymmetry
score calculated for each animal was expressed by the following
ratio: wall and ground touches of the ipsilateral forepaw—wall
and ground touches of the contralateral forepaw/wall and ground
touches of the ipsilateral forepaw+wall and ground touches of the
contralateral forepaw.
Somatosensory deficits were measured using the adhesive
removal test. Two small pieces of adhesive-backed paper dots of
equal size used as bilateral tactile stimuli occupying the distal–
radial region were placed at the wrist of each forelimb. The time
to remove each stimulus was documented. An asymmetry score
calculated for each animal was expressed by the following ratio:
time to remove the ipsilateral dot—time to remove the contralat-
eral dot/time to remove the ipsilateral dot+time to remove the
contralateral dot.
TISSUE PROCESSING
Twenty-eight days after ischemia, animals were anesthetized and
transcardially perfused with 4% paraformaldehyde in 0.1 mol/L
phosphate buffer. The brains were fixed in 4% paraformaldehyde
at 4◦C and then cryoprotected in 30% sucrose solution. Tissue
was stored at−80◦C until analysis.
DETERMINATION OF INFARCT SIZE
Lesion volumes were estimated by measurement of the maximum
diameter and measurement of the maximum infarct areas on
the slides, as previously described (Müller et al., 2008). Because
infarct size and tissue loss do not always match, an additional
analysis of the remaining cortical tissue was performed at the level
of the largest infarct extension.
IMMUNOHISTOCHEMISTRY
Immunohistochemistry was performed on coronal free-floating
40 µm sections with the following antibodies: anti-NeuN
(1:200; Millipore, Darmstadt, Germany), rat anti-BrdU (1:500;
Abcam, Cambridge, UK), mouse anti-neuronal nuclei and rat
anti-CD31 (1:250; Abcam), anti-Iba1 (raised in goat, 1:200,
Abcam, Cambridge, UK). Detection of anti-NeuN antibodies was
done with a goat anti-mouse fluorescent dye (AlexaFluor488,
1:100, 45 min.; MolecularProbes, Leiden, Netherlands). Bromod-
eoxyuridine antibodies were detected using a biotin conjugated
goat-anti-rat antibody (1:500; 45 min; Jackson Labs, West Grove,
PA, USA); CD31-antibodies detection was done using a biotin
conjugated goat-anti-rat antibody (1:100; 45 min; Jackson Labs).
Detection of Iba1-antibodies was performed using a biotin con-
jugated donkey anti-goat antibody (1:200, 45 min, room temper-
ature, Jackson Labs, West Grove, PA, USA).
For signal amplification of BrdU-, CD31- and Iba1-signal,
sections were incubated with horseradish peroxidase/streptavidin
(1:100, 45 min; DAKO, Glostrup, Denmark) and biotinyl tyra-
mide (1:100). Bromodeoxyuridine, CD31- and Iba1-positive cells
were visualized by a streptavidin/fluorescent dye (AlexaFluor594,
Molecular Probes). Nuclei counterstain was done with a tissue
preserving medium containing 4′,6-diamidino-2-phenylindole
(DAPI, Vector, Burlingame, CA, USA). Immunoflurescence was
computed and visualized with a Nikon Eclipse 80i fluorescence
microscope (Nikon, Düsseldorf, Germany) equipped with proper
filter sets for AlexaFluor594, AlexaFluor488 and DAPI.
ANALYSIS OF THE CELLULAR INFLAMMATORY RESPONSE
Quantification of Iba1-positive cells was performed by count-
ing absolute cell amounts covering four random squares
(200 × 200 µm) within the ipsilateral boundary zone of the
infarct of four separate brain sections per animal.
ANALYSIS OF NEUROGENESIS
Quantification of neurogenesis was performed as described pre-
viously (Diederich et al., 2012a). Briefly, BrdU/NeuN-positive
cells were analyzed in three brain regions: the dentate gyrus
(DG), subventricular zone (SVZ), and peri-infarct area (PI).
In the DG and SVZ, all BrdU-positive cells were counted
on seven sections (every 12th section, 440-µm intervals) per
hemisphere. For the analysis of BrdU/NeuN-positive cells in
the PI, four squares (300 µm × 300 µm) adjacent to
the PI were analyzed on four sections (bregma 1 mm to
−0.5 mm). To determine the percentage of neurons among
the newly generated cells, 50 randomly selected BrdU-positive
cells within the DG, SVZ, and PI, respectively, were analyzed
for BrdU/NeuN co-labeling. Multiplying the total number of
BrdU-positive cells with the percentage of NeuN/BrdU, double-
positive cells yielded the number of new neurons in the respective
areas.
Analysis of angiogenesis
Vessel length was determined by calculating the area of CD31
staining using ImageJ v1.34 software program (NIH). Three areas
(20× magnification) depicting the ischemic border zone from
three sections per animal, respectively, were photographed and
subsequently analyzed. Vessel cross-sectional surface area and
perimeter were measured using Neurolucida (MicroBrightField).
Two vessels featuring a minimum length of 300 µm for two
sections were analyzed per animal.
Primary and secondary objectives of the study
According to the ARRIVE guidelines primary and secondary
objectives were defined (Kilkenny et al., 2010). The primary
endpoint was functional outcome after ischemia. Secondary end-
points were the structural outcome as analyzed by the generation
of new neurons and angiogenesis as well as infarct size.
Statistical analysis
Randomization was carried out by the computer software
“Research Randomizer” (Version 3.0; Urbaniak GC, Plous S,
2011, retrieved on March 23, 2011, from www.randomizer.org/).
The values presented in this study are means ± SEM. Statistical
analyses were calculated using the Statistical Package of Social Sci-
ences (Version 15.0; SPSS Inc., Chicago, IL, USA). The normality
distribution of the data was assessed by graphical examination of
the histograms and verified by the Shapiro-Wilk test (P > 0.05).
Behavioral measurements were analyzed by area under the curve
analysis using analysis of variance (ANOVA) followed by the
Fisher protected least significant difference test. Student t-test
with Bonferroni correction was used to compare data between
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two groups. An α error rate of 0.05 was taken as the criterion for
significance.
RESULTS
All experiments were performed on a total number of 55 animals
(placebo: n = 13, G-CSF: n = 14, BM-MNC: n = 4, BM-MNC and
G-CSF: n = 14).
FUNCTIONAL OUTCOME
The photothrombotic stroke model causes distinct deficits in
somatosensory and motor functions. Somatosensory recovery
was evaluated by the adhesive removal test (Figure 1A) and motor
recovery by means of the cylinder test (Figure 1B). A summarized
analysis of the functional recovery was performed by means of
the area under the curve. Baseline performance was compara-
ble between all treatment groups. As expected, animals of all
experimental groups exhibited notable deficits in somatosensory
and motor function following photothrombotic stroke, which
subsequently attenuate over the course of 28 days until the end
of the experiment (Figures 1A,B).
The area under the curve analysis of the adhesive removal test
revealed a statistically significant decrease of the somatosensory
deficit in G-CSF (P < 0.01, Fisher protected least significant
difference post hoc test after significant ANOVA, Figure 1A) and
in the G-CSF+BM-MNC (P < 0.05) treated animals compared
to vehicle treated animals. In addition, G-CSF treated animals
also displayed a significantly improved somatosensory recovery
compared to animals treated with BM-MNC alone (P < 0.05).
The area under the curve analysis of the cylinder test did not
reveal any significant treatment effects on the recovery of motor
functions (P = 0.859; one-way ANOVA, Figure 1B).
INFARCT VOLUMES
As expected after photothrombotic stroke, infarct volumes did not
differ between the four groups (P = 0.877; ANOVA, Figure 2A).
ANALYSIS POSTISCHEMIC INFLAMMATION
To investigate treatment effects on postischemic inflammation
in the chronic phase following ischemia we analyzed the extent
of the inflammatory response 28 days after infarct induction.
FIGURE 1 | Assessment of neurological deficits. Somatosensory recovery
was assessed by the adhesive removal test (A). Animals of all
experimental groups exhibited notable deficits in somatosensory function
following photothrombotic stroke, which subsequently attenuate over the
course of 28 days until the end of the experiment. The area under the
curve (AUC) analysis revealed a significantly improved functional recovery
after G-CSF monotherapy and G-CSF + BM-MNC combination (*P < 0.05,
**p < 0.01; Fisher protected least significant difference post hoc test after
significant ANOVA). Motor recovery was assessed by the cylinder test
(B). Animals of all experimental groups showed deficits in motor function,
which attenuate over the course of 28 days until the end of the
experiment. The AUC analysis of the cylinder test did not reveal any
significant treatment effects on the recovery of motor functions
(P = 0.859; one-way ANOVA).
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FIGURE 2 | Analyses of infarct volumes and the postischemic
inflammatory response 28 days after photothrombotic stroke. Infarct
volumes (A) did not differ between the treatment groups (P = 0.877;
one-way ANOVA). There was no statistical difference between the groups
regarding the number of activated microglia cells (Iba1-positive, (B)) in the
boundary zone of the infarct (P = 0.976; one-way ANOVA).
The number of Iba1-positive cells with retracted processes and
round cell bodies, representing activated microglia, did not dif-
fer between the different groups (P = 0.976; one-way ANOVA,
Figure 2B).
QUANTIFICATION OF POSTISCHEMIC NEUROGENESIS
The analysis of postischemic neurogenesis revealed no signif-
icant treatment effects on the generation of new neurons in
any of the analyzed regions in postischemic brains of SH
animals (Figures 3A–E). As expected, the amount of BrdU/NeuN
immunoreactive cells was significantly elevated in the SVZ of
the ipsilateral compared to the contralateral hemisphere in ani-
mals of all treatment groups (ipsilateral vs. contralateral, control
group: P < 0.05; BM-MNC group: P < 0.001; G-CSF group:
P < 0.01; BM-MNC+G-CSF group: P < 0.01, Students t- test
with Bonferroni correction, Figure 3B). A comparison of the
treatment groups did not reveal significant treatment effects on
the amount of newborn neurons in the SVZ in either of the
two hemispheres (ipsilateral: P = 0.101, contralateral: P = 0.108;
multivariate ANOVA, Figure 3B). Furthermore, no treatment
effects on postischemic neurogenesis were detected in the DG
and in the PI (DG ipsilateral: P = 0.948, contralateral: P = 0.743;
ANOVA, Figure 3A/PI P = 0.095; one-way ANOVA, Figure 3C).
In the DG, no differences were found between the contralateral
and ipsilateral hemisphere (ipsilateral vs. contralateral control
group: P = 0.830; BM-MNC group: P = 0.637; G-CSF group:
P = 0.349; BM-MNC+G-CSF group: P = 0.907, Students t-test
with Bonferroni correction, Figure 3A).
QUANTIFICATION OF POSTISCHEMIC ANGIOGENESIS
To investigate effects of the different treatment groups on angio-
genesis (Figures 4A–D), blood vessel length was assessed at the
ischemic border zone. There was no difference in vessel length
between the groups (P = 0.236, one-way ANOVA, Figure 4A).
In addition, analysis of individual vessels revealed no qualitative
FIGURE 3 | Analysis of post-stroke neurogenesis. Quantification of
neurogenesis by detection of BrdU/NeuN-expressing cells in the dentate
gyrus (DG, A), subventicular zone (SVZ, B), and peri-infarct area (PI,
C) (*P < 0.05, **P < 0.01, ***P < 0.001; Student t-test with Bonferroni
correction). Representative photomicrographs from the DG (D) and SVZ
(E) demonstrating BrdU/NeuN-expressing cells.
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FIGURE 4 | Analysis of post-stroke angiogenesis. Quantification
of total vascular length per area (A). The vessel length per area
did not differ between the groups (P = 0.236; ANOVA). Analysis
of vessel surface area (B) and perimeter (C). No qualitative
changes in surface area (P = 0.949; ANOVA) and volume
(P = 0.848; ANOVA) were detected. (D) Representative
photomicrographs demonstrating blood vessels (CD31) within the
peri-infarct region.
changes in surface area (P = 0.949, one-way ANOVA, Figure 4B)
and volume (P = 0.848, one-way ANOVA, Figure 4C).
DISCUSSION
The present study investigated the hypothesis that the combi-
nation of G-CSF and BM-MNCs is more effective than either
treatment alone. Granulocyte-colony stimulating factor treated
rats, either in combination with BM-MNCs or alone, showed a
significantly improved functional recovery compared to placebo
rats measured by the adhesive removal test. In contrast, early
BM-MNC monotherapy did not improve somatosensory reha-
bilitation. Regeneration of gross motor function as tested by the
cylinder test remained unaffected in animals of all treatment
groups. The observed improvement of functional recovery in
G-CSF-treated animals was not due to infarct volume reduc-
tion, thus suggesting a true recovery-enhancing effect of G-CSF
rather than neuroprotective actions. Post-stroke neurogenesis and
angiogenesis were not significantly enhanced after G-CSF treat-
ment. Furthermore, the extent of the local inflammatory response
to cerebral ischemia were comparable in all treatment groups.
Initial reports indicated that treatment with BM-MNC might
reduce neurological impairment in animal models of focal cere-
bral ischemia after application in acute and subacute phases
(Iihoshi et al., 2004; Kamiya et al., 2008; Brenneman et al.,
2009; Giraldi-Guimarães et al., 2009; Nakano-Doi et al., 2010;
Kasam et al., 2012). However, there is cumulating evidence, that
the efficacy and therapeutic applicability of BM-MNC-treatment
might be more limited than initially anticipated. In contrast to
previous studies which used healthy animals, a recently published
study from our group could not demonstrate beneficial effects
of early BM-MNC treatment following transient middle cere-
bral artery occlusion (MCAO) in SH animals. Infarct volumes,
early behavioral outcomes, and the extent of the immediate
inflammatory response to cerebral ischemia were not affected
by BM-MNC treatment in co-morbid animals (Minnerup et al.,
2014).
In addition, timing of cell administration may have limited the
therapeutic impact of BM-MNC transplantation as a therapeutic
efficacy of BM-MNC application was previously shown for a
time window between 3 h and 7 days only (Iihoshi et al., 2004;
Vasconcelos-dos-Santos et al., 2012). Since we found that BM-
MNC in combination with G-CSF treatment time-dependently
abolished the beneficial effect of G-CSF on long-term functional
rehabilitation after MCAO in co-morbid SH animals (Pösel et al.,
2014), we chose 1 h as the time point for BM-MNC applica-
tion to reduce the likeliness for such detrimental interaction.
Whether this very early timing has contributed to the lack of
therapeutic impact remains for further investigation. However,
the most important difference in our study design is the use
of co-morbid animals as opposed to healthy animals. In fact,
divergent results on effect size with greater infarct size reduc-
tions in healthy animals compared to animals with comor-
bidities were previously reported (Crossley et al., 2008). The
predominant use of young and healthy animals in preclinical
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studies is assumed to contribute considerably to the transla-
tional failure in experimental stroke research (Crossley et al.,
2008).
While the efficacy of BM-MNC treatment on post-stroke
regeneration is diminished by the occurrence of co-morbidities,
the rehabilitative effects of G-CSF are still ascertainable, albeit
seemingly less pronounced. Zhao et al. (2007b) reported
limited and unstable long-term functional improvement follow-
ing MCAO in SH rats when G-CSF was administered daily, 3 h to
7 days after ischemia. When G-CSF treatment was delayed until
3.5 month after MCAO no functional benefit could be ascer-
tained (Zhao et al., 2007a). In accordance with these findings,
we detected a limited efficacy of G-CSF treatment following pho-
tothrombotic stroke in SH rats. While long-term somatosensory
function was improved, as revealed by the adhesive removal test,
the cylinder test did not detect any differences in motor function.
In contrast, we recently demonstrated, that G-CSF monother-
apy led to a robust improvement of both qualities following
photothrombotic stroke in normotensive rats of the same age
(Diederich et al., 2012b).
Granulocyte-colony stimulating factor treatment as well as
transplantation of BM-MNC both potentiate angiogenesis and
neurogenesis (Lee et al., 2005; Schneider et al., 2005; Giraldi-
Guimarães et al., 2009; Nakano-Doi et al., 2010) after ischemia
in normotensive animals. These mechanisms are suggested to
be primarily mediating long-term neurorehabilitation in non-
comorbid animals (Kojima et al., 2010; Osman et al., 2011).
Increased neurogenesis (Kronenberg et al., 2007) and angio-
genesis (Yang et al., 2011) occur in SH animals, regarded as
part of a counter-regulatory repair process against hypertension-
induced brain damage. Our results demonstrate, that in SH
animals, these repair mechanisms are not enhanced by G-CSF-
treatment following stroke and therefore do not mediate G-CSF-
induced functional improvement. These findings indicate, that
therapeutic modulation of angiogenesis and neurogenesis may
be crucially limited by comorbid disease, which might result in
reduced effectiveness. A potential explanation therefore might be
an exhausted angiogenic and neurogenic reserve, as suggested for
neurodegenerative diseases (Kempermann, 2008).
Transplanted BM-MNCs (Brenneman et al., 2009) as well as
G-CSF (Sehara et al., 2007; Solaroglu et al., 2009; Dietel et al.,
2012) exert neuroprotective anti-inflammatory actions after cere-
bral ischemia in normotensive animals. In SH animals, however,
BM-MNC treatment did not affect the local microglial immune
response after MCAO (Minnerup et al., 2014). In the current
study, we investigated treatment effects on postischemic local
inflammation in the chronic phase 28 days after photothrombotic
stroke. Neither the respective monotherapies with BM-MNCs
and G-CSF, nor the combination of both resulted in an altered
local microglial response. This result indicates, that local inflam-
mation might not be directly responsible for improved long-
term functional recovery following G-CSF treatment. However,
hypertension has been shown to entail systemic vascular inflam-
mation including chronic activation of microglia (Zubcevic et al.,
2011) and may therefore influence poststroke immune responses
(Möller et al., 2014) and might also interfere with the therapeutic
potential of G-CSF and BM-MNC.
Our study has strength and limitations. The experiments
were conducted in concordance with recommendations for good
preclinical stroke research (Sutherland et al., 2012) and rig-
orously adhered to stringent quality criteria in experimental
stroke research such as randomization, surgery and evaluations
performed in a blinded fashion, and controlled physiological
parameters. Furthermore, the use of animals with a relevant
comorbidity may increase the predictive value of the presented
findings regarding a human stroke patient population. While we
could demonstrate G-CSF-induced improvements in long-term
functional recovery following cortical ischemia in co-morbid
animals, the underlying mechanism remains to be determined.
Analyses of post-stroke angiogenesis might be confounded by
hypertension-related endothelial abnormalities. Further research
is needed to determine how co-morbidities like hypertension
affect post-stroke repair mechanisms. The results of the present
study cannot be attributed to the co-morbid condition of the
animals with absolute certainty, since no control groups of healthy
animals were included in the present study. Future preclinical
stroke studies on co-morbid animals should also include groups
of healthy animals in order to determine whether the obtained
results can be directly attributed to the comorbid condition. In
the present study, we focused on syngenic BM-MNC transplan-
tation as it simulates autologous transplantation. Bone marrow
derived mononuclear cells derived from normotensive rats might
differ in their phenotype and thus in their therapeutic capacity
as compared to BM-MNC derived from hypertensive rats used
in the present study. Further research is needed to determine
the therapeutic potential of BM-MNCs and their limitations,
including analysis of their cytokine profiles. The cell numbers
used in our experiments were based on previous studies that
investigated different intravenous cell therapies in animal stroke
models (Minnerup et al., 2011). However, we cannot rule out that
the use of a higher BM-MNC dose might have yielded different
results.
Our study confirms the beneficial effect of G-CSF treatment
on long-term functional recovery following cortical stroke in
hypertensive animals. Angiogenesis and neurogenesis, which are
regarded as decisive mechanisms of G-CSF-mediated regenera-
tion in normotensive animals, remained unaffected by G-CSF
treatment in hypertensive animals. Contrary to our hypothesis,
the combination of G-CSF and BM-MNC was not more effective
than G-CSF alone and the monotherapy with BM-MNC was
without any effect on functional recovery. The reduced efficacy
of G-CSF treatment and the absence of any beneficial effect of
BM-MNC transplantation might be attributed to hypertension-
related morbidity. The findings of our study further corrob-
orate the importance of evaluating the efficacy of treatments
and determining the underlying neuroregenerative mechanisms
in animal models more adequately reflecting the characteristic
pathophysiological state of stroke patients.
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